Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Aparna R. Parikh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5245-7841; OpenAlex author ID A5006888122, A5034115525. Sources: ClinicalTrials.gov.

Their work

Papers
15
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
94
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers, 1 trial · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 15

  1. Therapeutic Targeting of Epithelial-Mesenchymal Cellular Plasticity in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-25-2052↗
  2. Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancer Co-author DOI 10.64898/2026.08.06.26359422↗
  3. Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Co-author DOI 10.1200/po-25-00332↗
  4. Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006131↗
  5. Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-human translational studies. Co-author DOI 10.7150/thno.100116↗
  6. Underlying Bias in the Treatment of Pancreatic Cancer: Minorities Treated at the Same Facilities are Less Likely to Receive Neoadjuvant Therapy. Co-author DOI 10.1097/sla.0000000000005354↗
  7. Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis. Co-author DOI 10.1097/xcs.0000000000000499↗
  8. Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000004585↗
  9. Supportive Oncology Care at Home Intervention for Patients With Pancreatic Cancer. Co-author DOI 10.1200/op.22.00088↗
  10. Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. Co-author DOI 10.1007/s11605-020-04897-9↗
  11. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Co-author DOI 10.1038/s43018-021-00269-7↗
  12. Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-0099↗
  13. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical… Co-author DOI 10.1001/jamaoncol.2019.0892↗
  14. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000002600↗
  15. Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer. Co-author DOI 10.1245/s10434-018-6832-8↗

Trials 1

  1. Predicting Disease Progression and/or Recurrence in Cancer Principal investigator NCT04776837↗

Closest collaborators

The 25 strongest of 94 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Colin D. Weekes · 11 shared papers, 2019–2026 · strength 1.51
  2. Theodore Sunki Hong · 12 shared papers, 2018–2026 · strength 1.49
  3. Jennifer Yon-Li Wo · 11 shared papers, 2018–2026 · strength 1.34
  4. Lawrence Scott Blaszkowsky · 8 shared papers, 2019–2026 · strength 1.11
  5. David P. Ryan · 9 shared papers, 2019–2026 · strength 1.08
  6. David Tsai Ting · 8 shared papers, 2019–2026 · strength 1.03
  7. Motaz Qadan · 8 shared papers, 2019–2024 · strength 1.02
  8. Cristina Rosa Ferrone · 8 shared papers, 2018–2024 · strength 0.95
  9. Keith D. Lillemoe · 7 shared papers, 2019–2024 · strength 0.87
  10. Carlos F. Fernandez-del Castillo · 5 shared papers, 2018–2023 · strength 0.62
  11. Zhi Ven Fong · 3 shared papers, 2023–2024 · strength 0.50
  12. Hannah Johnson Roberts · 3 shared papers, 2024–2026 · strength 0.50
  13. Ryan David Nipp · 5 shared papers, 2018–2022 · strength 0.42
  14. Onofrio A. Catalano · 3 shared papers, 2021–2024 · strength 0.38
  15. Priyadarshini Pathak · 2 shared papers, 2024–2026 · strength 0.37
  16. Thomas Adam Abrams · 2 shared papers, 2025–2026 · strength 0.34
  17. Matthew B.B. Yurgelun · 2 shared papers, 2025–2026 · strength 0.34
  18. Brian Matthew Wolpin · 2 shared papers, 2025–2026 · strength 0.34
  19. Joseph Douglas Mancias · 2 shared papers, 2025–2026 · strength 0.34
  20. James M. Cleary · 2 shared papers, 2025–2026 · strength 0.34
  21. Fidel López‐Verdugo · 2 shared papers, 2023 · strength 0.33
  22. Carlos Fernández-del Castillo · 3 shared papers, 2019–2024 · strength 0.32
  23. Vikram Deshpande · 3 shared papers, 2019–2022 · strength 0.31
  24. Arnav Mehta · 2 shared papers, 2021–2026 · strength 0.27
  25. Janet E. Murphy · 3 shared papers, 2019–2022 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.